GT Biopharma, Inc. (GTBP) Operating income 2016–2025
GT Biopharma, Inc. (GTBP) annual operating income history from SEC filings — each fiscal year as reported.
-$12.4MFY2025 · since FY2016: -$9.4M → -$12.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.4M | +13.5% |
| FY2024 | -$14.4M | -5.8% |
| FY2023 | -$13.6M | +36.1% |
| FY2022 | -$21.3M | +63.0% |
| FY2021 | -$57.5M | -750.3% |
| FY2020 | -$6.8M | -142.1% |
| FY2019 | $16.1M | +106.4% |
| FY2018 | -$250.1M | -84.5% |
| FY2017 | -$135.6M | -1346.2% |
| FY2016 | -$9.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GTBP financial trends
GTBP RevenueGTBP Net incomeGTBP Net marginGTBP Gross profitGTBP Gross marginGTBP Operating marginGTBP Operating cash flowGTBP Free cash flowGTBP Capital expendituresGTBP Return on equityGTBP Stock buybacksGTBP Dividends paidGTBP Total assetsGTBP Total liabilitiesGTBP Shareholders’ equityGTBP overview →